MedDataX Logo

Seven Year Update of Macular Degeneration Patients

NCT01256827 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2013-11-14

No results posted yet for this study

Summary

The purpose is to assess long term vision outcomes and disease status in patients with age-related macular degeneration previously treated with ranibizumab as participants in the Phase 3 ANCHOR and MARINA Studies and the HORIZON Study.

Conditions

  • Age-related Macular Degeneration

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of California, San Francisco

    lead OTHER

Principal Investigators

  • Robert B. Bhisitkul, MD, PhD · University of California, San Francisco

  • David S. Boyer, MD · Retina-Vitreous Associates

  • SriniVas Sadda, MD · USC Keck School of Medicine, Doheny Eye Institute

  • Kang Zhang, MD, PhD · University of California San Diego, Shiley Eye Center

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-10-31
Completion
2013-04-30

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01256827 on ClinicalTrials.gov